Physician profile
Mary Stringfellow
NPI 1194743849
$5,381.09
in general payments reported to CMS, 2019-2025
57 companies · $1,102 in 2025
The $1,102 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $378 · 2021: $114 · 2022: $1,262 · 2023: $1,045 · 2024: $1,205 · 2025: $1,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,352.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $820.84 | 2022-2025 | Calquence, Imfinzi, Enhertu |
| Regeneron Healthcare Solutions, INC. | $295.80 | 2022-2024 | Dupixent |
| Janssen Biotech, INC. | $295.25 | 2022-2025 | Darzalex, Tecvayli, Rybrevant |
| Novartis Pharmaceuticals Corporation | $276.79 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $258.47 | 2022-2024 | Keytruda, Welireg, Reblozyl |
| Ucb, INC. | $220.54 | 2019-2023 | Briviact |
| Pharmacosmos Therapeutics INC. | $217.50 | 2023-2025 | Monoferric |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.16 | 2019-2023 | Ofev |
| Pfizer INC. | $166.10 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $159.44 | 2022-2024 | Ultomiris, Soliris |
| Genzyme Corporation | $155.61 | 2022-2024 | |
| Daiichi Sankyo INC. | $144.70 | 2022-2025 | Datroway, Enhertu, Injectafer |
| United Therapeutics Corporation | $120.50 | 2020-2024 | Tyvaso |
| Genentech USA, INC. | $118.64 | 2023-2025 | Polivy, Columvi, Lunsumio |
| Celgene Corporation | $111.79 | 2023-2025 | Reblozyl, Opdualag |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Stringfellow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.